Moderna also has TAA encoded mRNA vaccine products under clinical development, such as mRNA‐5671 for the treatment of patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant advanced cancers (NCT03948763, Table 2). This evidence concerns the gene KRAS and cancer.